Objective: To review the efficacy, safety, pharmacokinetics, pharmacodynamics, administration, drug interactions, and cost of dolutegravir (Tivicay), a third in class integrase strand transfer inhibitor (INSTI), for the treatment of human immunodeficiency virus (HIV-1) in adults. Data Sources: MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches (January 2000 to May 2014) were conducted for articles published in English and limited to human subjects, using the key words antiretroviral drugs, HIV integrase strand transfer inhibitors, dolutegravir, DTG, and S/GSK1349572. Study Selection and Data Extraction: Following MEDLINE, International Pharmaceutical Abstracts, ClinicalTrials.gov, and Google Scholar searches, 6 clinical trials were identified and included in this review. Phase III/IV studies evaluating the safety and efficacy of dolutegravir in humans were selected and evaluated. Data Synthesis: In treatment naïve and experienced patients dolutegravir was noninferior to raltegravir at suppressing viral load when added to background therapy. Abacavir/lamivudine/dolutegravir was noninferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate and darunavir/ritonavir plus background therapy at suppressing viral load. In patients with multiple-class antiretroviral resistance at baseline, dolutegravir decreased HIV RNA by 1.4 log10 copies/mL at day 8, 63% of patients had achieved virologic suppression at week 8, and retained potency in treatment-experienced INSTI-resistant patients up to week 48 or 96 of follow-up. Conclusion: Dolutegravir is a safe, effective, and well-tolerated treatment option for adults with HIV-1, even in the setting of resistance to other antiretrovirals.
NyamweyaSHegedusAJayeARowland-JonesSFlanaganKLMacallanDC. Comparing HIV-1 and HIV-2 infection: lessons for viral immunopathogenesis. Rev Med Virol. 2013;23:221-240.
CastroKGWardJWSlutskerL. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19. http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm. Accessed May 15, 2014.
7.
Tivicay (dolutegravir) [package insert].Research Triangle Park, NC: ViiV Healthcare; August2013.
8.
MocroftAVellaSBenfieldTL. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet. 1998;352:1725-1730.
9.
PalellaFJDelaneyKMMoormanAC. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
10.
VittinghoffEScheerSO’MalleyPColfaxGHolmbergSDBuchbinderSP. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999;179:717-720.
11.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed May 15, 2014. Table 3.
12.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed May 15, 2014. Section E-1.
13.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed May 15, 2014. Section C-5.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Section accessed May 15, 2014. Table 5a.
18.
GerettiAMArmeniaDCeccherini-SilbersteinF. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis. 2012;25:677-686.
19.
KarmonSLMarkowitzM. Next-generation integrase inhibitors: where to after raltegravir?Drugs. 2013;73:213-228.
20.
MinSSongIBorlandJ. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254-258.
21.
MinSSloanLDejesusE. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults. AIDS. 2011;25:1737-1745.
22.
LunzenJMaggioloFArribasJR. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naïve adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomized, phase 2b trial. Lancet Infect Dis. 2012;12:111-118.
23.
SongIBorlandJChenS. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56:1627-1629.
24.
CastellinoSMossLWagnerD. Metabolism, excretion, and mass balance of the HIV-1 integrase inhibitor dolutegravir in humans. Antimicrob Agents Chemother. 2013;57:3536-3546.
25.
RaffiFRachlisAStellbrinkHJ. Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomized, double-blind, non-inferiority SPRING-2 study. Lancet Infect Dis. 2013;381:735-743.
26.
WalmsleySAntelaAClumeckN. Dolutegravir (DTG;S/GSK1349572) + abacavir/lamivudine once daily statistically superior to tenofovir/emtricitabine/efavirenz: 48-week results—SINGLE (ING114467). Abstract presented at: 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); San Francisco, CA; September 9-12, 2012 (Abstract H-556b).
27.
CahnPPozniakALMingroneH. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naïve adults with HIV: week 48 results from the randomized, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700-708.
28.
CastagnaAMaggioloFPencoG. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 Study. J Infect Dis. 2014;210:354-362.
29.
ViiV Healthcare, Research Triangle Park, NC. Study assessing dolutegravir in HIV-1 infected subjects with virus resistant to raltegravir and/or elvitegravir (VIKING-4). In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT01568892?term=viking-4&rank=1. Accessed July 9, 2014.
30.
Viiv Healthcare, Research Triangle Park, NC. Dolutegravir compared to darunavir/ritonavir, each in combination with dual nucleoside reverse transcriptase inhibitors (NRTIs) in ART-naïve subjects (FLAMINGO). In: ClinicaTrials.gov [Internet]. Bethesda, MD: National Library of Medicine. http://clinicaltrials.gov/ct2/show/NCT01449929?term=flamingo&rank=1. Accessed July 9, 2014.
RaffiFJaegerHMottaD. Dolutegravir is non-inferior to raltegravir and shows durable response through 96 weeks: results from the SPRING-2 trial. Poster presented at: 7th IAS Conference on HIVE Pathogenesis, Treatment and Prevention; Kuala Lumpur, Malaysia; July 2, 2013 (Poster TULBPE17).
33.
FeinbergJClotetBKhuongM. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviral-naïve adults: 48 week results from FLAMINGO (ING114915). Abstract presented at: the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Denver, CO; September12, 2013 (Abstract H-1464a).
FantauzziATurrizianiOMezzaromaI. Potential benefit of dolutegravir once daily: efficacy and safety. HIV AIDS (Auckl). 2013;5:29-40.
36.
EronJClotetBDurantJ. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis. 2013;207:704-708.
37.
SongIBorlandJChenS. Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572. Br J Clin Pharmacol. 2011;72:103-108.
38.
SongIMinSSBorlandJ. The effect of lopinavir/ritonavir and darunavir/ritonavir on the HIV integrase inhibitor S/GSK1349572 in healthy participants. J Clin Pharmacol. 2011;51:237-242.
39.
SongIBorlandJChenS. Effect of fosamprenavir/ritonavir on the pharmacokinetics of the integrase inhibitor, dolutegravir, in healthy subjects. Abstract presented at: Fifty-first Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL; September 17-29, 2011 (Abstract 1727).
40.
SongIMinSSBorlandJ. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr. 2010;55:365-367.
41.
SongIBorandKMinS. Effects of ritravirine alone with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55:3517-3521.
42.
PatelPSongIBorlandJ. Evaluation of antacid and multivitamin effects on S/GSK1349572 pharmacokinetics in healthy volunteers. J Antimicrob Chemother. 2011;66:1567-1572.
43.
SongIBorlandJChenSSavinaPPeppercornAFPiscitelliS. Effect of prednisone on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2013;57:4394-4397.
44.
SongIMarkSChenS. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects. Drug Alcohol Depend. 2013;133:781-784.
45.
SongIBorlandJSavinaPM. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharm Drug Dev. 2013;2:342-348.
46.
KoteffJBorlandJChenS. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75:990-996.
47.
WellerSBorlandJChenS. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2014;70:29-35.
48.
Tivicay (dolutegravir sodium). Red book online [Internet database]. Greenwood Village, CO: Thompson Micromedex. Updated periodically.
49.
Isentress (raltegravir potassium). Red book online [Internet database]. Greenwood Village, CO: Thompson Micromedex. Updated periodically.
50.
Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate). Red book online [Internet database]. Greenwood Village, CO: Thompson Micromedex. Updated periodically.
